Compare ASIC & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASIC | CERT |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | United States | United States |
| Employees | 203 | N/A |
| Industry | Property-Casualty Insurers | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 930.6M | 860.9M |
| IPO Year | N/A | 2020 |
| Metric | ASIC | CERT |
|---|---|---|
| Price | $20.66 | $5.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $26.75 | $11.67 |
| AVG Volume (30 Days) | 46.6K | ★ 3.5M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,838,000.00 |
| Revenue This Year | $34.21 | $4.18 |
| Revenue Next Year | $34.65 | $5.39 |
| P/E Ratio | $98.60 | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $16.35 | $5.19 |
| 52 Week High | $23.88 | $13.94 |
| Indicator | ASIC | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 51.70 | 43.58 |
| Support Level | $20.32 | $5.19 |
| Resistance Level | $20.67 | $6.48 |
| Average True Range (ATR) | 0.57 | 0.29 |
| MACD | -0.05 | 0.05 |
| Stochastic Oscillator | 30.00 | 42.45 |
Ategrity Specialty Insurance Co Holdings is a specialty property and casualty insurance holding company focused on the excess and surplus market for small to medium-sized businesses (SMBs) across the United States. Operating through its subsidiaries, the company underwrites small and medium-sized commercial risks across selected industry verticals, including Retail, Real Estate, Hospitality, and Construction. Its operating model uses a technology-driven method to standardize, simplify, and, where appropriate, automate these transactions. The group distributes its products through licensed surplus lines brokers and wholesale agents.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.